Year: 2023

ShapeTX to Showcase Groundbreaking Advances in CNS in vivo RNA Editing, CNS-Targeting AAVs, and TruStable™ AAV Manufacturing at the J.P. Morgan 41st Annual Healthcare Conference

SEATTLE, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ShapeTX today announced Francois Vigneault, Ph.D., Co-founder and Chief Executive Officer, will present...

Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract

Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022Procurement Triggered by Positive Top-Line Data from Pilot Efficacy...

Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced

New round of financing led by Vensana Capital will support technology platform expansion and further validating VX1, Volta’s Artificial Intelligence...

Orion and Amneal enter strategic partnership – Orion receives exclusive licence to commercialise Amneal’s generic products in Europe, Australia and New Zealand

ORION CORPORATION PRESS RELEASE 4 JANUARY 2023 at 16.00 EET Orion and Amneal enter strategic partnership – Orion receives exclusive...

Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219

COVALENT-111, now underway in the US, has completed Phase I and is currently enrolling type 2 diabetes patients in the Phase...

Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023

MORRISTOWN, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development...

error: Content is protected !!